Polyneuron announces the completion of a CHF 3.1 million seed financing, following the receipt of a second tranche. Furthermore, the company’s management team and the board of directors have been strengthened. Press release
In other news
-
Financing
Polyneuron raises CHF 22.5 million in an oversubscribed… [read on]
Polyneuron raises CHF 22.5 million in a major Series A financing -
Awards
After a first grant of CHF 10’000 during Phase… [read on]
Polyneuron supported by BaseLaunch Accelerator -
Awards
Polyneuron was selected into phase I of the new BaseLaunch… [read on]
Polyneuron participates in BaseLaunch Accelerator -
General
Polyneuron has obtained the orphan drug designation from the European… [read on]
EMA Orphan Drug Designation for PN-1007 -
General
Polyneuron publishes top PN-1007 in vivo data in the renowned… [read on]
PN-1007 article published in PNAS -
Awards
Polyneuron is proud to announce that it has obtained the… [read on]
CTI Start-up Label -
Awards
Polyneuron is listed Top5 among the best Swiss Biotech Startups… [read on]
Top5 Swiss Biotech Startup -
Awards
Polyneuron got selected out of more than 120 European neuroscience… [read on]
Brain Forum Innovation Award -
Financing
Polyneuron announced it has completed a seed financing round raising… [read on]
Polyneuron completes seed financing round -
General
Polyneuron is one of the 25 winners of the renowned… [read on]
IMD StartUp Competition -
General
We are proud to announce that Polyneuron is ranked 39th… [read on]
Polyneuron is listed in the TOP 100 of the best Swiss Startups 2015 -
Awards
Polyneuron is in the top5 start-up teams at the Science4Life… [read on]
4th place at Science4Life